KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Total Current Liabilities: 2009-2025

Historic Total Current Liabilities for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Sep 2025 value amounting to $4.5 billion.

  • Vertex Pharmaceuticals' Total Current Liabilities rose 12.64% to $4.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 billion, marking a year-over-year increase of 12.64%. This contributed to the annual value of $3.6 billion for FY2024, which is 0.48% up from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' Total Current Liabilities stood at $4.5 billion, which was up 8.14% from $4.1 billion recorded in Q2 2025.
  • Vertex Pharmaceuticals' 5-year Total Current Liabilities high stood at $4.5 billion for Q3 2025, and its period low was $1.8 billion during Q2 2021.
  • Over the past 3 years, Vertex Pharmaceuticals' median Total Current Liabilities value was $3.6 billion (recorded in 2023), while the average stood at $3.7 billion.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Total Current Liabilities dropped by 4.48% in 2021, and later spiked by 39.19% in 2022.
  • Quarterly analysis of 5 years shows Vertex Pharmaceuticals' Total Current Liabilities stood at $2.1 billion in 2021, then grew by 28.02% to $2.7 billion in 2022, then climbed by 29.37% to $3.5 billion in 2023, then rose by 0.48% to $3.6 billion in 2024, then increased by 12.64% to $4.5 billion in 2025.
  • Its Total Current Liabilities was $4.5 billion in Q3 2025, compared to $4.1 billion in Q2 2025 and $3.8 billion in Q1 2025.